New trial seeks best chemo strategy for childhood muscle cancer
NCT ID NCT07466316
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two chemotherapy plans for people with newly diagnosed intermediate-risk rhabdomyosarcoma, a type of muscle cancer. One group gets a higher dose of chemo over a shorter time, while the other gets a lower dose over a longer time plus extra maintenance drugs. The goal is to see which approach works better and has fewer side effects. About 342 participants up to age 50 will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHABDOMYOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.